Tokyo Tape
Sign in
← PHC Holdings

Quarterly report · Q3

6523.TEDINET S100Q6BS
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥265.1bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥94.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Revenue¥340.5bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥252.4bn2021-04-01 → 2021-12-31Cons.Revenue IFRS
Revenue¥86.3bn2021-10-01 → 2021-12-31dCons.Revenue IFRS
Operating income¥21.4bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥10.9bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Operating income¥24.1bn2021-04-01 → 2021-12-31Cons.Operating profit loss IFRS
Operating income¥10.5bn2021-10-01 → 2021-12-31dCons.Operating profit loss IFRS
Profit before tax¥7.4bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥4.0bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Profit before tax¥3.0bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥24.9bn2021-04-01 → 2021-12-31Cons.Profit loss before tax IFRS
Profit before tax¥4.8bn2021-10-01 → 2021-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥3.4bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥8.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥18.5bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.5bn2021-10-01 → 2021-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥3.6bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥2.2bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Net income¥18.6bn2021-04-01 → 2021-12-31Cons.Profit loss IFRS
Net income¥3.6bn2021-10-01 → 2021-12-31dCons.Profit loss IFRS
Total assets¥569.9bnat 2022-12-31Cons.Assets IFRS
Total assets¥591.3bnat 2022-03-31Cons.Assets IFRS
Total assets¥595.1bnat 2021-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥431.1bnat 2022-12-31Cons.Liabilities IFRS
Total liabilities¥455.3bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥138.8bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥136.1bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥152.1bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥107.6bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥137.9bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥135.4bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥151.5bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥59.4bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.2bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥88.0bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥6.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥51.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥36.0bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥11.3bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥12.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥9.4bn2021-04-01 → 2021-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥32.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥7.0bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥106m2021-04-01 → 2021-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥27.332022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥17.692022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥-70.782021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥156.672021-04-01 → 2021-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥28.832021-10-01 → 2021-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥27.072022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥17.532022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥-70.782021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥152.822021-04-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥28.342021-10-01 → 2021-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio24.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio22.9%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio25.5%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31¥1.8bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥1.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥13.0bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue2022-04-01 → 2022-12-31¥83.7bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue external2022-04-01 → 2022-12-31¥83.7bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentsegment profit2022-04-01 → 2022-12-31¥19.7bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2022-04-01 → 2022-12-31¥80.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2022-04-01 → 2022-12-31¥80.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.3bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue2022-04-01 → 2022-12-31¥99.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue external2022-04-01 → 2022-12-31¥99.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentsegment profit2022-04-01 → 2022-12-31¥8.5bn
—segment totalrevenue2022-04-01 → 2022-12-31¥263.3bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥263.3bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥34.4bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31¥2.1bn
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2021-12-31¥2.1bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥11.7bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue2021-04-01 → 2021-12-31¥82.3bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue external2021-04-01 → 2021-12-31¥82.3bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentsegment profit2021-04-01 → 2021-12-31¥18.7bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2021-04-01 → 2021-12-31¥68.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2021-04-01 → 2021-12-31¥68.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2021-04-01 → 2021-12-31¥4.6bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue2021-04-01 → 2021-12-31¥99.6bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue external2021-04-01 → 2021-12-31¥99.6bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentsegment profit2021-04-01 → 2021-12-31¥12.4bn
—segment totalrevenue2021-04-01 → 2021-12-31¥250.3bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥250.3bn
—segment totalsegment profit2021-04-01 → 2021-12-31¥35.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 934
ItemContextValueUnit
Payments for purchase of treasury shares fin cf IFRSCurrentYTDDuration－JPY
Proceeds from sale of treasury shares fin cf IFRSPrior1YTDDuration36000000JPY
Proceeds from sale of treasury shares fin cf IFRSCurrentYTDDuration－JPY
Dividends paid to owners of parent fin cf IFRSPrior1YTDDuration－JPY
Dividends paid to owners of parent fin cf IFRSCurrentYTDDuration-8890000000JPY
Other fin cf IFRSPrior1YTDDuration-60000000JPY
Other fin cf IFRSCurrentYTDDuration-105000000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration106000000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-32874000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration519000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration1419000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration27226000000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration-35864000000JPY
Cash and cash equivalents IFRSPrior2YearInstant60762000000JPY
Cash and cash equivalents IFRSPrior1YearInstant95232000000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant87988000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant59368000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember82257000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember99632000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember68376000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember250266000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember2101000000JPY
Revenue from external customers IFRSPrior1YTDDuration252368000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember82257000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember99632000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember68376000000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember250266000000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember2101000000JPY
Revenue IFRSPrior1YTDDuration252368000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember18742000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember12441000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember4583000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember35768000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-11704000000JPY
Operating profit loss IFRSPrior1YTDDuration24063000000JPY
Finance income IFRSPrior1YTDDuration3075000000JPY
Finance costs IFRSPrior1YTDDuration2231000000JPY
Profit loss before tax IFRSPrior1YTDDuration24907000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember10123000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember7830000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember5042000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReportableSegmentsMember22997000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_ReconcilingItemsMember472000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration23469000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass